BTIG raised the firm’s price target on Palvella Therapeutics (PVLA) to $215 from $192 and keeps a Buy rating on the shares. The firm is positive on the company achieving a highly compelling and statistically significant win in the phase 3 SEVLA trial for QTORIN rapamycin in microcystic lymphatic malformations, an indication with over 30K pts in the US alone and no FDA approved therapies, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Robust Phase 3 SELVA Results for QTORIN Rapamycin Drive Confident Buy Rating on PVLA
- Palvella Therapeutics announces $150M proposed public offering of common stock
- Palvella Therapeutics price target raised to $210 from $190 at Truist
- Palvella Therapeutics price target raised to $209 from $143 at JonesResearch
- Palvella Therapeutics price target raised to $210 from $174 at Chardan